Kymera Therapeutics, Inc.

KYMRSEC EDGAR

Biological Products, (No Diagnostic Substances)(DE)CIK: 1815442

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue from Contract with Customer, Excluding Assessed Tax	$78.6M	$46.8M	$72.8M	$34.0M	$2.9M
Cost of Revenue	$78.6M	$46.8M	—	—	—
Research and Development Expense	$189.1M	$164.2M	$137.0M	$62.1M	$37.2M
Operating Expenses	$244.1M	$208.1M	$173.4M	$80.3M	$45.1M
Operating Income (Loss)	-$165.5M	-$161.3M	-$100.5M	-$46.3M	-$42.2M
Other Nonoperating Income (Expense)	$18.6M	$6.4M	$313.0K	$711.0K	$959.0K
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest	-$311.4M	—

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Assets	$978.0M	$575.8M	$603.1M	$605.9M	$487.2M
Assets, Current	$510.3M	$405.3M	$419.4M	$451.3M	$302.3M
Cash and Cash Equivalents, at Carrying Value	$110.0M	$68.4M	$48.0M	$31.0M	$76.0M
Accounts Receivable, after Allowance for Credit Loss, Current	—	$15.0M	$0.00	—	—
Liabilities	$142.4M	$180.8M	$113.0M	$146.3M	$203.3M
Liabilities, Current	$67.8M	$85.7M	$71.3M	$92.5M	$110.6M
Accounts Payable, Current	$6.0M	$7.1M	$4.3M	$4.0M

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Net Cash Provided by (Used in) Operating Activities	-$102.8M	-$153.1M	-$128.9M	$88.1M	$17.9M
Net Cash Provided by (Used in) Investing Activities	$139.9M	$20.5M	-$99.8M	-$422.6M	-$16.5M
Net Cash Provided by (Used in) Financing Activities	$4.2M	$153.0M	$250.3M	$289.3M	$34.9M
Payments to Acquire Property, Plant, and Equipment	$34.5M	$2.8M	$1.6M	$9.1M	$532.0K

Access SEC EDGAR data via REST API. Free tier available.

from sec_edgar import SecEdgar

api = SecEdgar("YOUR_KEY")
api.revenue("AAPL", limit=5)